The year in atherothrombosis

Journal of the American College of Cardiology

Volumn 60, Issue 10, 2012, Pages 932-942

  Sanz, Javier ^a   Moreno, Pedro R ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; imaging; risk factors; thrombosis; vasculature

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; DALCETRAPIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PLACEBO; PROTON PUMP INHIBITOR; RIVAROXABAN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA;

ACUTE CORONARY SYNDROME; ALZHEIMER DISEASE; ANGIOGENESIS; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; ECHOGRAPHY; HEALTH BEHAVIOR; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOSIS; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; EARLY DIAGNOSIS; FIBRINOLYTIC AGENTS; HEALTH BEHAVIOR; HEALTH CARE COSTS; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MEDICATION ADHERENCE; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; STENTS; THROMBOSIS; UNITED STATES; WORLD HEALTH;

EID: 84865459936     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.04.045     Document Type: Review

References (103)

1. D.M. Lloyd-Jones, Y. Hong, D. Labarthe Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond Circulation 121 2010 586 613
2. S.A. Wartak, J. Friderici, A. Lotfi Patients' knowledge of risk and protective factors for cardiovascular disease Am J Cardiol 107 2011 1480 1488
3. C. Bambs, K.E. Kip, A. Dinga, S.R. Mulukutla, A.N. Aiyer, S.E. Reis Low prevalence of "ideal cardiovascular health" in a community-based population: the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study Circulation 123 2011 850 857
4. A.R. Folsom, H. Yatsuya, J.A. Nettleton, P.L. Lutsey, M. Cushman, W.D. Rosamond Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence J Am Coll Cardiol 57 2011 1690 1696
5. G. Danaei, M.M. Finucane, Y. Lu National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
6. M.M. Finucane, G.A. Stevens, M.J. Cowan National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants Lancet 377 2011 557 567
7. G. Danaei, M.M. Finucane, J.K. Lin National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants Lancet 377 2011 568 577
8. F. Farzadfar, M.M. Finucane, G. Danaei National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants Lancet 377 2011 578 586
9. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
10. K. Dudas, G. Lappas, S. Stewart, A. Rosengren Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006) Circulation 123 2011 46 52
11. T.G. Briffa, M.S. Hobbs, A. Tonkin Population trends of recurrent coronary heart disease event rates remain high Circ Cardiovasc Qual Outcomes 4 2011 107 113
12. E.M. Small, E.N. Olson Pervasive roles of microRNAs in cardiovascular biology Nature 469 2011 336 342
13. K. Bidzhekov, L. Gan, B. Denecke microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans Thromb Haemost 107 2012 619 625
14. G. Nakazawa, F. Otsuka, M. Nakano The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
15. S.J. Kang, G.S. Mintz, T. Akasaka Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation Circulation 123 2011 2954 2963
16. K. Yamaji, K. Inoue, T. Nakahashi Bare metal stent thrombosis and in-stent neoatherosclerosis Circ Cardiovasc Interv 5 2012 47 54
17. K. Tanaka, D. Nagata, Y. Hirata, Y. Tabata, R. Nagai, M. Sata Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice Atherosclerosis 215 2011 366 373
18. K.R. Purushothaman, M. Purushothaman, P. Muntner Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis Vasc Med 16 2011 103 108
19. X.W. Cheng, H. Song, T. Sasaki Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice Hypertension 57 2011 981 989
20. I. Bot, J.W. Jukema, I.M. Lankhuizen, T.J. van Berkel, E.A. Biessen Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels Atherosclerosis 214 2011 295 300
21. A.M. Carneiro, D. Barthelmes, M.S. Falcao Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab Ophthalmologica 225 2011 211 221
22. G. Aparicio-Gallego, F.J. Afonso-Afonso, L. Leon-Mateos Molecular basis of hypertension side effects induced by sunitinib Anticancer Drugs 22 2011 1 8
23. A. Joutel, M. Monet-Lepretre, C. Gosele Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease J Clin Invest 120 2010 433 445
24. J.C. Kovacic, P. Moreno, E.G. Nabel, V. Hachinski, V. Fuster Cellular senescence, vascular disease, and aging: part 2 of a 2-part review Clinical vascular disease in the elderly Circulation 123 2011 1900 1910
25. S. Kaffashian, A. Dugravot, H. Nabi Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study Eur Heart J 32 2011 2326 2332
26. M. Guerchet, V. Aboyans, P. Nubukpo, P. Lacroix, J.P. Clement, P.M. Preux Ankle-brachial index as a marker of cognitive impairment and dementia in general population A systematic review Atherosclerosis 216 2011 251 257
27. C. McGorrian, S. Yusuf, S. Islam Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART modifiable risk score Eur Heart J 32 2011 581 589
28. A.P. Defilippis, M.J. Blaha, C.E. Ndumele The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 58 2011 2076 2083
29. M. Oberg, M.S. Jaakkola, A. Woodward, A. Peruga, A. Pruss-Ustun Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries Lancet 377 2011 139 146
30. G.D. Simonetti, R. Schwertz, M. Klett, G.F. Hoffmann, F. Schaefer, E. Wuhl Determinants of blood pressure in preschool children: the role of parental smoking Circulation 123 2011 292 298
31. J.G. Ayer, E. Belousova, J.A. Harmer, C. David, G.B. Marks, D.S. Celermajer Maternal cigarette smoking is associated with reduced high-density lipoprotein cholesterol in healthy 8-year-old children Eur Heart J 32 2011 2446 2453
32. R.R. Huxley, M. Woodward Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies Lancet 378 2011 1297 1305
33. A. Tirosh, I. Shai, A. Afek Adolescent BMI trajectory and risk of diabetes versus coronary disease N Engl J Med 364 2011 1315 1325
34. M. Juonala, C.G. Magnussen, G.S. Berenson Childhood adiposity, adult adiposity, and cardiovascular risk factors N Engl J Med 365 2011 1876 1885
35. D. Wormser, S. Kaptoge, E. Di Angelantonio Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies Lancet 377 2011 1085 1095
36. C.K. Chow, S. Islam, L. Bautista Parental history and myocardial infarction risk across the world: the INTERHEART Study J Am Coll Cardiol 57 2011 619 627
37. S. Gupta, A. Rohatgi, C.R. Ayers Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality Circulation 123 2011 1377 1383
38. A.D. Sniderman, K. Williams, J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
39. V. Veeranna, S.K. Zalawadiya, A. Niraj Homocysteine and reclassification of cardiovascular disease risk J Am Coll Cardiol 58 2011 1025 1033
40. M.J. Blaha, M.J. Budoff, A.P. DeFilippis Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study Lancet 378 2011 684 692
41. S. Mohlenkamp, N. Lehmann, S. Moebus Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality J Am Coll Cardiol 57 2011 1455 1464
42. J. Rubin, H.J. Chang, K. Nasir Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population Circ Cardiovasc Imaging 4 2011 201 209
43. S.G. Wannamethee, P. Welsh, G.D. Lowe N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease J Am Coll Cardiol 58 2011 56 64
44. J.T. Saunders, V. Nambi, J.A. de Lemos Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study Circulation 123 2011 1367 1376
45. K. Sundquist, M. Winkleby, X. Li, J. Ji, K. Hemminki, J. Sundquist Familiar transmission of coronary heart disease: a cohort study of 80,214 Swedish adoptees linked to their biological and adoptive parents Am Heart J 162 2011 317 323
46. H. Schunkert, I.R. Konig, S. Kathiresan Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease Nat Genet 43 2011 333 338
47. The Coronary Artery Disease (C4D) Genetics Consortium A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease Nat Genet 43 2011 339 344
48. J.C. Bis, M. Kavousi, N. Franceschini Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque Nat Genet 43 2011 940 947
49. A. Dehghan, J. Dupuis, M. Barbalic Meta-analysis of genome-wide association studies in >80,000 subjects identifies multiple loci for C-reactive protein levels Circulation 123 2011 731 738
50. A.A. Hussein, K. Uno, K. Wolski Peripheral arterial disease and progression of coronary atherosclerosis J Am Coll Cardiol 57 2011 1220 1225
51. G.W. Stone, A. Maehara, A.J. Lansky A prospective natural-history study of coronary atherosclerosis N Engl J Med 364 2011 226 235
52. T. Yonetsu, T. Kakuta, T. Lee In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography Eur Heart J 32 2011 1251 1259
53. J.F. Polak, M.J. Pencina, K.M. Pencina, C.J. O'Donnell, P.A. Wolf, R.B. D'Agostino Sr Carotid-wall intima-media thickness and cardiovascular events N Engl J Med 365 2011 213 221
54. R. Blankstein, M.J. Budoff, L.J. Shaw Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 58 2011 364 374
55. E.A. Hulten, S. Carbonaro, S.P. Petrillo, J.D. Mitchell, T.C. Villines Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis J Am Coll Cardiol 57 2011 1237 1247
56. F.Y. Lin, L.J. Shaw, A.M. Dunning Mortality risk in symptomatic patients with nonobstructive coronary artery disease: a prospective 2-center study of 2,583 patients undergoing 64-detector row coronary computed tomographic angiography J Am Coll Cardiol 58 2011 510 519
57. N. Altaf, S.D. Goode, A. Beech Plaque hemorrhage is a marker of thromboembolic activity in patients with symptomatic carotid disease Radiology 258 2011 538 545
58. T. Noguchi, N. Yamada, M. Higashi, Y. Goto, H. Naito High-intensity signals in carotid plaques on T1-weighted magnetic resonance imaging predict coronary events in patients with coronary artery disease J Am Coll Cardiol 58 2011 416 422
59. C.H. Jansen, D. Perera, M.R. Makowski Detection of intracoronary thrombus by magnetic resonance imaging in patients with acute myocardial infarction Circulation 124 2011 416 424
60. D. Moguillansky, X. Leng, A. Carson Quantification of plaque neovascularization using contrast ultrasound: a histologic validation Eur Heart J 32 2011 646 653
61. E. Vucic, S.D. Dickson, C. Calcagno Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging J Am Coll Cardiol Img 4 2011 1100 1109
62. M. Mizoguchi, N. Tahara, A. Tahara Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta J Am Coll Cardiol Img 4 2011 1110 1118
63. E.J. Folco, Y. Sheikine, V.Z. Rocha Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography J Am Coll Cardiol 58 2011 603 614
64. J.M. Richards, S.I. Semple, T.J. MacGillivray Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study Circ Cardiovasc Imaging 4 2011 274 281
65. K.C. Briley-Saebo, Y.S. Cho, P.X. Shaw Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes J Am Coll Cardiol 57 2011 337 347
66. F. Hyafil, E. Vucic, J.C. Cornily Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases Eur Heart J 32 2011 1561 1571
67. C. von Bary, M. Makowski, A. Preissel MRI of coronary wall remodeling in a swine model of coronary injury using an elastin-binding contrast agent Circ Cardiovasc Imaging 4 2011 147 155
68. F.A. Jaffer, M.A. Calfon, A. Rosenthal Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury J Am Coll Cardiol 57 2011 2516 2526
69. J.R. Banegas, E. Lopez-Garcia, J. Dallongeville Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study Eur Heart J 32 2011 2143 2152
70. P.P. Cacoub, U. Zeymer, T. Limbourg Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) registry Europe Heart 97 2011 660 667
71. W.B. Borden, R.F. Redberg, A.I. Mushlin, D. Dai, L.A. Kaltenbach, J.A. Spertus Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention JAMA 305 2011 1882 1889
72. R.L. Pande, T.S. Perlstein, J.A. Beckman, M.A. Creager Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004 Circulation 124 2011 17 23
73. S. Yusuf, S. Islam, C.K. Chow Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey Lancet 378 2011 1231 1243
74. V. Fuster, B.B. Kelly, R. Vedanthan Promoting global cardiovascular health: moving forward Circulation 123 2011 1671 1678
75. S.P. Kishore, R. Vedanthan, V. Fuster Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries J Am Coll Cardiol 57 2011 1980 1987
76. N.K. Choudhry, J. Avorn, R.J. Glynn Full coverage for preventive medications after myocardial infarction N Engl J Med 365 2011 2088 2097
77. P. Muntner, D. Mann, R.P. Wildman, D. Shimbo, V. Fuster, M. Woodward Projected impact of polypill use among US adults: medication use, cardiovascular risk reduction, and side effects Am Heart J 161 2011 719 725
78. C.M. Kastorini, H.J. Milionis, K. Esposito, D. Giugliano, J.A. Goudevenos, D.B. Panagiotakos The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals J Am Coll Cardiol 57 2011 1299 1313
79. C.P. Wen, J.P. Wai, M.K. Tsai Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study Lancet 378 2011 1244 1253
80. W.S. Weintraub, S.R. Daniels, L.E. Burke Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association Circulation 124 2011 967 990
81. L.D. Lazar, M.J. Pletcher, P.G. Coxson, K. Bibbins-Domingo, L. Goldman Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Circulation 124 2011 146 153
82. M. Domanski, D. Lloyd-Jones, V. Fuster, S. Grundy Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol 8 2011 721 725
83. N.K. Choudhry, A.R. Patrick, R.J. Glynn, J. Avorn The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels J Am Coll Cardiol 57 2011 784 791
84. E. Jonathan, B. Derrick, L. Emma C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study Lancet 377 2011 469 476
85. S.J. Nicholls, C.M. Ballantyne, P.J. Barter Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
86. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
87. Z.A. Fayad, V. Mani, M. Woodward Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
88. A.V. Khera, M. Cuchel, M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
89. P.J. Patel, A.V. Khera, K. Jafri, R.L. Wilensky, D.J. Rader The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease J Am Coll Cardiol 58 2011 2068 2075
90. S.J. Griffin, K. Borch-Johnsen, M.J. Davies Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial Lancet 378 2011 156 167
91. S. Bangalore, S. Kumar, I. Lobach, F.H. Messerli Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials Circulation 123 2011 2799 2810
92. G. Mancia, H. Schumacher, J. Redon Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) Circulation 124 2011 1727 1736
93. H.C. Gerstein, M.E. Miller, S. Genuth Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 2011 818 828
94. T.K. Schramm, G.H. Gislason, A. Vaag Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J 32 2011 1900 1908
95. T. Simon, P.G. Steg, M. Gilard Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry Circulation 123 2011 474 482
96. M.J. Price, P.B. Berger, P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
97. G. Parodi, R. Marcucci, R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
98. J.L. Mega, W. Hochholzer, A.L. Frelinger III Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
99. K.W. Mahaffey, D.M. Wojdyla, K. Carroll Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 124 2011 544 554
100. J.H. Alexander, R.D. Lopes, S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
101. J. Oldgren, A. Budaj, C.B. Granger Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
102. P. Tricoci, Z. Huang, C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2011 20 33
103. J.L. Mega, E. Braunwald, S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2011 9 19